Bone Biologics Corporation (BBLGW) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 13Aug 18Aug 21Aug 26Aug 31Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.3x

Market Cap

$4.76M

MomentumView details →

1D Return

−32.50%

YTD Return

−74.06%

RSI (14)

25.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.3x

Market Cap

$4.76M

RSI (14)

25.9

MomentumView details →

1D Return

−32.50%

YTD Return

−74.06%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−73.66%

ROA (TTM)

−65.16%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+58.67%

FCF YoY

+20.59%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+45.13%

EBITDA YoY

+48.62%

EarningsView details →

EPS (Actual)

−$0.43

EPS Surprise

0.00%

Beats (12Q)

0/12

Next Q EPS Est

−$0.19

Avg Surprise (4Q)

−0.10%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

8.67x

Quick Ratio

8.67x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−2.89M

Op. CF (TTM)

−2.63M

Next earningsDec 2, 2026 →

Latest newsMore news →

Bone Biologics Corporation announced that the validated shelf life of its rhNELL-1 protein has been extended to 32 months, enhancing manufacturing and distribution flexibility ahead of pivotal-study scale.24d ago

Bone Biologics Corp signed a $3.0 million at-the-market private placement agreement with an institutional investor, issuing common stock and pre-funded warrants, plus Series F and Series G warrants, with $3.0 million in upfront gross proceeds and up to $6.0 million additional from warrant exercises.58d ago

Similar companies

Autonomix Medical, Inc. Common StockAMIX Nexalin Technology, Inc.NXL Pheton Holdings Ltd Class A Ordinary SharesPTHL Inspira Technologies Oxy B.H.N. Ltd.IINNW Vivos Therapeutics, Inc.VVOS Bluejay Diagnostics, Inc.BJDX Find similar companies →

Latest newsMore news →

Bone Biologics Corporation announced that the validated shelf life of its rhNELL-1 protein has been extended to 32 months, enhancing manufacturing and distribution flexibility ahead of pivotal-study scale.24d ago Bone Biologics Corp signed a $3.0 million at-the-market private placement agreement with an institutional investor, issuing common stock and pre-funded warrants, plus Series F and Series G warrants, with $3.0 million in upfront gross proceeds and up to $6.0 million additional from warrant exercises.58d ago